title: Use of bisphosphonates in prostate cancer: Current status.
abstract: Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer.
authors.affiliation: Department of Urology, All India Institute of Medical Sciences, New Delhi - 110 029, India.
authors.forename: Rishi
authors.initials: R
authors.lastname: Nayyar
authors.forename: Narmada P
authors.initials: NP
authors.lastname: Gupta
references.citation: J Urol. 2003 Jun;169(6):2008-12
references.pmid: 12771706
references.citation: BJU Int. 2004 Sep;94(4):524-7
references.pmid: 15329105
references.citation: Cancer. 2004 Mar 1;100(5):892-9
references.pmid: 14983482
references.citation: Br J Cancer. 2001 Apr 20;84(8):1126-34
references.pmid: 11308265
references.citation: Curr Opin Oncol. 2002 Nov;14(6):609-15
references.pmid: 12409650
references.citation: J Urol. 2002 Sep;168(3):1005-7
references.pmid: 12187209
references.citation: Int J Cancer. 1999 Oct 8;83(2):263-9
references.pmid: 10471537
references.citation: BMJ. 2003 Aug 30;327(7413):469
references.pmid: 12946966
references.citation: Clin Orthop Relat Res. 2004 Aug;(425):143-51
references.pmid: 15292799
references.citation: Cancer. 2001 Jun 15;91(12):2238-45
references.pmid: 11413511
references.citation: J Natl Cancer Inst. 2003 Sep 3;95(17):1300-11
references.pmid: 12953084
references.citation: J Urol. 2003 May;169(5):1735-7
references.pmid: 12686820
references.citation: Urol Clin North Am. 2004 May;31(2):313-9
references.pmid: 15123410
references.citation: J Bone Miner Res. 2004 Nov;19(11):1766-70
references.pmid: 15476575
references.citation: Geriatrics. 1999 Sep;54(9):20-2, 27-8, 30 passim
references.pmid: 10494225
references.citation: Cancer. 1997 Feb 1;79(3):545-50
references.pmid: 9028366
references.citation: BJU Int. 2005 May;95(7):935-8
references.pmid: 15839907
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: Urol Clin North Am. 2006 May;33(2):191-9, vi
references.pmid: 16631457
references.citation: Osteoporos Int. 1999;9 Suppl 2:S66-80
references.pmid: 10525729
references.citation: Med J Aust. 1997 Oct 20;167(8):412-5
references.pmid: 9364155
references.citation: N Engl J Med. 2001 Sep 27;345(13):948-55
references.pmid: 11575286
references.citation: CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
references.pmid: 16514137
references.citation: J Urol. 2002 Feb;167(2 Pt 1):535-8
references.pmid: 11792913
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4277-84
references.pmid: 14581438
references.citation: N Engl J Med. 2005 Jan 13;352(2):154-64
references.pmid: 15647578
references.citation: J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
references.pmid: 15173273
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3335-42
references.pmid: 12947070